Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Carson Advisory Inc.

Carson Advisory Inc. boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 60.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,655 shares of the life sciences company’s stock after purchasing an additional 1,000 shares during the quarter. Carson Advisory Inc.’s holdings in Illumina were worth $277,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new position in shares of Illumina during the fourth quarter valued at $282,000. Gryphon Financial Partners LLC boosted its stake in Illumina by 22.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 1,807 shares of the life sciences company’s stock valued at $252,000 after purchasing an additional 327 shares during the period. Principal Securities Inc. acquired a new position in Illumina during the 4th quarter valued at about $51,000. QRG Capital Management Inc. grew its position in Illumina by 62.9% in the 4th quarter. QRG Capital Management Inc. now owns 5,481 shares of the life sciences company’s stock worth $763,000 after purchasing an additional 2,117 shares during the last quarter. Finally, Ieq Capital LLC increased its stake in shares of Illumina by 144.9% in the fourth quarter. Ieq Capital LLC now owns 7,366 shares of the life sciences company’s stock valued at $1,026,000 after purchasing an additional 4,358 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Up 1.3 %

Shares of Illumina stock opened at $124.13 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $159.28. The firm has a market capitalization of $19.77 billion, a PE ratio of -15.23 and a beta of 1.15. The stock’s fifty day moving average is $122.13 and its 200-day moving average is $120.95.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company earned $0.32 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 3.89 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the subject of several analyst reports. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price objective for the company in a research report on Wednesday, August 14th. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. UBS Group lifted their price objective on shares of Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. Finally, Daiwa America raised shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.